Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2004-06-17
2009-02-03
Campell, Bruce (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S189100, C530S300000, C530S350000, C435S005000
Reexamination Certificate
active
07485312
ABSTRACT:
The invention relates to sequences of a novel variant of the Hepatitis B surface antigen (HBsAg) and to methods for detecting, in patient samples, nucleic acids, antigens and antibodies directed against the same.
REFERENCES:
patent: 5531990 (1996-07-01), Thanavala et al.
patent: 1 142 906 (2001-10-01), None
patent: 1 174 523 (2002-01-01), None
patent: 1 174 523 (2002-01-01), None
patent: WO 01/40279 (2001-06-01), None
patent: WO-02/079217 (2002-10-01), None
S. J. Friezner Degen et al., “The Murine Urokinase-Type Plasminogen Activator Gene,”Biochemistry, 26: 8270-8279 (1987).
K. M. Weinberger et al., “High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum,”Journal of General Virology, 81: 1165-1174 (2000).
M. P. Cooreman et al., “Characterization of the Reactivity Pattern of Murine Monoclonal Antibodies Against Wild-Type Hepatitis B Surface Antigen to G145R and Other Naturally Occuring “a” Loop Escape Mutations,”Hepatology, 11: 1287-1292 (1999).
W. F. Carman et al., “Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA,”The Lancet, 345: 1406-1407 (1995).
H-L. Chiou et al., “Altered antigenicity of ‘a’ determinant variants of hepatitis B virus,”Journal of General Virology, 78: 2639-2645 (1997).
Sequence No. Q96841 from: M. T. Moraes et al., “Sequence analysis of pre-S/S gene of hepatitis B virus strains of genotypes A, D, and F isolates,”Arch. Virol., 141:1767-1773 (1996).
Sequence No. EMBL: AB104715 from: N. Saudy et al., “Genotypes and phylogenetic characterization of hepatitis B and delta viruses in Egypt,”Journal of Medicial Virology, 70(4): 529-536 (2003).
Sequence No. AF280817 from: L. Yan et al., “First Chinese HBV strain: genotype D complete sequence report,” submitted (Jun. 21, 2000).
Sequence No. EMBL: HEB297881 from: L.F. Liu, “Wide variety of genotypes and geographical origins of hepatitis B virus in Belgian children.”
Sequence No. EMBL: HEB214660 from: I. Borchani-Chabchoub, “Genotyping of Tunisian hepatitis B virus isolates based on the sequencing of preS2 and S regions,”Microbes Infect., 2(6): 607-612 (2000).
R. Scopes,Protein Purification: Principles and Practice(3rdedition), Springer Verlag (1994), table of contents only.
E. Harlow et al.,Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1988), table of contents only.
Lee; “Hepatitis B Virus Infection”; The New England Journal of Medicine, vol. 337, No. 24, pp. 1733-1745, (1997).
Tiollais et al.; “The Hepatitis B Virus”; Nature, vol. 317, pp. 489-495, (1985).
Gerlich et al.; “Functions of Hepatitis B Virus Proteins and Virus Assembly”; Viral Hepatitis and Liver Disease, pp. 121-134, (1991).
Blum; “Variants of Hepatitis B, C and D Viruses: Molecular Biology and Clinical Significance”; Digestion, vol. 56, pp. 85-95, (1995).
Okamoto et al; “Genomic Heterogeneity of Hepatitis B Virus in a 54-Year-Old Woman Who Contracted the Infection Through Materno-Fetal Transmission”; Japan. J. Exp. Med., vol. 57, No. 4, pp. 231-236, (1987).
Carman et al.; “Viral Genetic Variation: Hepatitis B Virus as a Clinical Example”; The Lancet, vol. 341, pp. 349-353, (1993).
Coutroucé et al.; “Bibliotheca Haematologica No. 42”; pp. 1-19, (1976).
Norder et al.; “Molecular Basis of Hepatitis B Virus Serotype Variations Within the Four Major Subtypes”; Journal of General Virology, vol. 73, pp. 3141-3145, (1992).
Norder et al.; “Complete Genomes, Phylogenetic Relatedness, and Structural Proteins of Six Strains of the Hepatitis B Virus, Four of Which Represent Two New Genotypes”; Virology, vol. 198, pp. 489-503, (1994).
Cooreman et al.; “Characterization of the Reactivity Pattern of Murine Monoclonal Antibodies Against Wild-Type Hepatitis B Surface Antigen to G145R and Other Naturally Occurring “a” Loop Escape Mutations”; Hepatology, vol. 30, No. 5, pp. 1287-1292, (1999).
Terrault et al.; “Incidence and Clinical Consequences of Surface and Polymerase Gene Mutations in Liver Transplant Recipients on Hepatitis B Immunoglobulin”, Hepatology, vol. 28, No. 2, pp. 555-561, (1998).
Tillman et al.; “Mutational Pattern of Hepatitis B Virus on Sequential Therapy With Famciclovir and Lamivudine in Patients With Hepatitis B Virus Reinfection Occurring Under HBlg Immunoglobulin After Liver Transplantation”; Hepatology, vol. 30, No. 1, pp. 244-256, (1999).
Hunt et al.; “Clinical Relevance of Hepatitis B Viral Mutations”, Hepatology, vol. 31, No. 5, pp. 1037-1044, (2000).
Cooreman et al.; “Vaccine-and Hepatitis B Immune Globulin-Induced Escape Mutations of Hepatitis B Virus Surface Antigen”; J. Biomed. Sci., vol. 8, pp. 237-247, (2001).
Peterson et al.; “Antigenic Structure of Hepatitis B Surface Antigen: Identification of the “d” Subtype Determinant by Chemical Modification and Use of Monoclonal Antibodies”; The Journal of Immunology, vol. 132, No. 2, pp. 920-927, (1984).
JILG; “Novel Hepatitis B Vaccines”; Vaccine, vol. 16, pp. S65-S68, (1998).
Carman et al.; “Hepatitis B Virus Envelope Variation After Transplantation With and Without Hepatitis B Immune Globulin Prophylaxis”; Hepatology, vol. 24, No. 3, pp. 489-493, (1996).
Müller et al.; “Liver Transplantation in HBs Antigen (HBsAg) Carriers | Prevention of Hepatitis B Virus (HBV) Recurrence by Passive Immunization”; Journal of Hepatology, vol. 13, pp. 90-96, (1991).
Samuel et al.; “Liver Transplantation in European Patients With the Hepatitis B Surface Antigen”; The New England Journal of Medicine, vol. 329, No. 25, pp. 1842-1847, (1993).
Brind et al.; “Evidence for Selection of Hepatitis B Mutants After Liver Transplantation Through Peripheral Blood Mononuclear Cell Infection”; Journal of Hepatology, vol. 26, pp. 228-235, (1997).
Fisher et al.; “Hepatitis B Virus Variants Associated With Clinically Severe Recurrence After Liver Transplantation”; Transplantation Proceedings, vol. 31, pp. 492-493, (1999).
Ghany et al.; “Hepatitis B Virus S Mutant in Liver Transplant Recipients Who Were Reinfected Despite Hepatitis B Immune Globulin Prophylaxis”; Hepatology, vol. 27, No. 1, pp. 213-222, (1998).
Protzer-Knolle et al.; “Hepatitis B Virus With Antigenically Altered Hepatitis B Surface Antigen is Selected by High-Dose Hepatitis B Immue Globulin After Liver Transplantation”; Hepatology, vol. 27, No. 1, pp. 254-263, (1998).
Carman et al.; “Genetic Variation in Hepatitis B Virus”; Gastroenterology, vol. 102, No. 2, pp. 711-719, (1992).
Carman; “The Clinical Significance of Surface Antigen Variants of Hepatitis B Virus”; Journal of Viral Hepatitis, vol. 4, Suppl. 1, pp. 11-20, (1997).
Swenson et al.; “Determination of HBsAg Subtypes in Different High Risk Populations Using Monoclonal Antibodies”; Journal of Virological Methods, vol. 33, pp. 27-38, (1991).
Blitz et al.; “Antigenic Diversity of Hepatitis B Virus Strains of Genotype F in Amerindians and Other Population Groups From Venezuela”; Journal of Clinical Microbiology, vol. 36, No. 3, pp. 648-651, (1998).
Ashton-Rickardt et al.; “Mutations That Change the Immunological Subtype of Hepatitis B Virus Surface Antigen and Distinguish Between Antigenic and Immunogenic Determination”, Journal of Medical Virology, vol. 29, pp. 204-214, (1989).
Ohba et al.; “Relationships Between Serotypes and Genotypes of Hepatitis B Virus: Genetic Classification of HBV by Use of Surface Genes”; Virus Research, vol. 39, pp. 25-34, (1995)
Campell Bruce
Dade Behring Marburg GmbH
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Hurt Sharon
LandOfFree
Surface protein (HBsAg) variant of the hepatitis B virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Surface protein (HBsAg) variant of the hepatitis B virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Surface protein (HBsAg) variant of the hepatitis B virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4118012